Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma

NCT00335829 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT00335829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00335829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
February 28, 2011
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer